Karolinska Development divests shares in portfolio company OssDsign

Core Viewpoint - Karolinska Development AB has divested its remaining shares in OssDsign, resulting in a capital injection of approximately SEK 34.5 million, which strengthens the company's liquidity and allows for prioritization of other investments with greater value creation potential [1][2]. Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying breakthrough medical innovations in the Nordic region, investing in the creation and growth of companies that advance these innovations into commercial products [4][5]. - The company has access to world-class medical innovations from the Karolinska Institutet and other leading universities and research institutes in the Nordic region, aiming to build companies around leading scientists supported by experienced management teams [5][6]. Investment Strategy - The divestment from OssDsign reflects a strategic decision to realize profits and enhance the financial position of Karolinska Development, enabling the company to invest in other holdings with higher potential returns [2][3]. - Following the divestment, Karolinska Development has no direct ownership in OssDsign but retains indirect ownership through the KCIF Co-Investment Fund [3]. Portfolio and Management - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for life-threatening or serious debilitating diseases, led by an entrepreneurial team of investment professionals with a proven track record [6].